TherapeuticsMD (TXMD) Change in Receivables (2010 - 2022)

TherapeuticsMD has reported Change in Receivables for 13 years, with the latest figure at -$13.6 million in Q3 2022.

• For the quarter ending Q3 2022, Change in Receivables fell 439.82% year-over-year to -$13.6 million; the trailing twelve-month figure through Sep 2022 stood at -$4.3 million (down 130.19% YoY), and the FY2021 full-year result was $4.3 million, down 47.39% from the prior year.
• Change in Receivables for Q3 2022 stood at -$13.6 million, down from $11.1 million in the prior quarter.
• The five-year high for Change in Receivables was $11.1 million in Q2 2022, with the low at -$13.6 million in Q3 2022.
• Historically, Change in Receivables has averaged $1.6 million across 5 years, with a median of $790885.0 in 2018.
• Annual changes were most pronounced in 2018 — Change in Receivables plunged 2767.32% — and 2022, when it soared 48326.09%.
• TherapeuticsMD's Change in Receivables stood at -$1.8 million in 2018, then jumped by 629.91% to $9.3 million in 2019, then retreated by 7.4% to $8.6 million in 2020, then slumped by 114.32% to -$1.2 million in 2021, then tumbled by 1006.81% to -$13.6 million in 2022.
• The last three Change in Receivables figures came in at -$13.6 million (Q3 2022), $11.1 million (Q2 2022), and -$489000.0 (Q1 2022), per Business Quant data.